---
title: Efficacy of the ATP Switch Automatic Programming in Implantable Cardioverter Defibrillator (ICD) and Cardiac Resynchronization Therapy Defibrillator (CRT-D) Implanted Patients
nct_id: NCT01169246
overall_status: TERMINATED
sponsor: MicroPort CRM
study_type: OBSERVATIONAL
primary_condition: Ventricular Arrythmias
countries: France
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT01169246.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT01169246"
ct_last_update_post_date: 2019-03-25
last_seen_at: "2026-05-12T06:14:48.085Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Efficacy of the ATP Switch Automatic Programming in Implantable Cardioverter Defibrillator (ICD) and Cardiac Resynchronization Therapy Defibrillator (CRT-D) Implanted Patients

**Official Title:** Efficacy of the ATP Switch Automatic Programming in ICD and CRT-D Implanted Patients

**NCT ID:** [NCT01169246](https://clinicaltrials.gov/study/NCT01169246)

## Key Facts

- **Status:** TERMINATED
- **Why Stopped:** Low recruitement rate
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 1254
- **Lead Sponsor:** MicroPort CRM
- **Collaborators:** Sorin Group France SAS
- **Conditions:** Ventricular Arrythmias
- **Start Date:** 2009-11
- **Completion Date:** 2015-02
- **CT.gov Last Update:** 2019-03-25

## Brief Summary

Primary objective is to assess the efficacy of the new ATP Autoswitch function in simple, dual or triple chamber ICD.

## Detailed Description

The efficacy rate of the ATP Auto-switch function, defined as the % of VT episodes successfully reduced, will be compared with 85%.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* The patient has been implanted (primo implantation or replacement) with an ICD model PARADYM VR 8250, DR 8550, CRT 8750, CRT 8770 models or any similar or higher range device
* ATP Auto-switch function is programmed ON

Exclusion Criteria:

* Presence of a contra-indication to the ICD therapy
* Life expectancy less than 12 months
```

## Arms

- **Paradym VR, DR and CRT models**

## Primary Outcomes

- **Ventricular Tachyarrhythmia episode** _(time frame: 2 years)_ — % of VT episode successfully reduced by the ATP Auto-switch

## Secondary Outcomes

- **Arrhythmia incidence** _(time frame: 2 years)_

## Locations (1)

- CHU Brest, Brest, France

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.whyStopped` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.chu brest|brest||france` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT01169246.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT01169246*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*